FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease

The Food and Drug Administration authorized a gene remedy from Bluebird Bio Inc. that represents a possible remedy for a uncommon blood dysfunction at a worth of $2.8 million per affected person, making it one of many nation’s most costly medicine.

The FDA on Wednesday cleared the remedy, Zynteglo, for sufferers who depend on common blood transfusions due to a genetic illness known as beta-thalassemia, which interferes with the manufacturing of hemoglobin, a protein in pink blood cells that carries oxygen all through the physique.